Ponatinim wins early FDA nod

The FDA has approved ponatinib (Iclusig), a third-generation tyrosine kinase inhibitor, to treat two forms of drug-resistant leukemia, the agency said. The approved indications include chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults. Approval was based on a single phase II trial, results of which were reported last week at the American Society of Hematology's annual meeting. Read more here.